Mun, Sung Soo
Meyerberg, Jeremy
Peraro, Leila
Korontsvit, Tatyana
Gardner, Thomas
Malviya, Manish
Kyi, Chrisann
O’Cearbhaill, Roisin E.
Liu, Cheng
Dao, Tao
Scheinberg, David A.
Funding for this research was provided by:
NIH (RO1 CA55349, PO1 CA23766, P30 CA008748, R35 CA241894)
Article History
Received: 2 May 2023
Accepted: 14 August 2023
First Online: 27 August 2023
Declarations
:
: DAS is on a board of, has equity in, receives research funding from, has licensed technology with, or income from Lantheus, Sellas, Iovance, Arvinas, Clade, Pfizer, Actinium, Oncopep, Repertoire, Sapience, Atengen, CoImmune, and Eureka Therapeutics. TD is a consultant of Eureka Therapeutics. REO reports personal fees from Tesaro/GSK, Regeneron, Seattle Genetics, Fresenius Kabi, Gynecologic Oncology Foundation, Bayer, Curio/Onclive, R-Pharm, and Immunogen, other from Hitech Health, outside the submitted work. She is a non-compensated steering committee member for the PRIMA, Moonstone (Tesaro/GSK) and DUO-O (AstraZeneca) studies and non-compensated advisor for Carina Biotech. Her institute receives funding for clinical research from Bayer/Celgene/Juno, Tesaro/GSK, Merck, Ludwig Cancer Institute, Abbvie/StemCentrx, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, MarkerTherapeutics, Syndax Pharmaceuticals, Genmab/Seagen Therapeutics, Sellas Therapeutics, Genentech, Kite Pharma, and Gynecologic Oncology Foundation. LP is now an employee of Beam. TG is now an employee of Arsenal. All other authors declare no conflict or competing interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB Human Subject Assurance Number FW00004998) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.